Latest Breaking News On - Matt gline - Page 1 : comparemela.com

Roivant Sciences Ltd (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript

Roivant Sciences Ltd (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Frank tortiMatt glineDavid risingerDouglas tsaoMayukh sukhatmeYaron werberAbby beierBristol myers squibbCorinne johnsonAndy chenLouise chenYatin sunejaPiper sandlerBrian chengAllison bratzelWolfe research

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomNew yorkStephanie leeSumitomo pharmaGoldman sachsMatt glineExchange commissionDevelopment expensesSecurities exchangeRoivant sciences ltdRoivant sciencesUs district courtTreatment failureGrave disease

Roivant Sciences (ROIV) Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, $1 5B Share Buyback

Roivant Sciences (ROIV) Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, $1 5B Share Buyback
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBen zimmerSumitomo pharmaMatt glineQuan dong nguyenStanford university school of medicineByers eye institutePriovant therapeuticsTreatment failureStanford university school

Roivant Stock Leafrogs Its 50-Day Line On Extremely Positive Eye Drug Test

Roivant Stock Leafrogs Its 50-Day Line On Extremely Positive Eye Drug Test
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

Matt glineLeerink risingerDavid risingerRoivant sciencesRoivant chief executive matt glineBusiness daily

Roivant Sciences to Discontinue RVT-2001 Development in Myelodysplastic Syndrome

Investigation of RVT-2001 will be discontinued following an insufficient display of benefit in patients with myelodysplastic syndrome.

Matt glineRoivant sciencesInternational prognostic scoring systemLower risk mdsMyelodysplastic syndromeRvt 2001